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ABSTRACT
Focused ultrasound (FUS) is a non-invasive treatment modality that can
produce therapeutic effects in localized regions of tissue through thermal ele-
vations or mechanical stresses caused by an ultrasound wave. Although FUS
therapy is effective at treating many different diseases, FUS therapy can be
expensive and time-consuming because the treatment must be planned and
monitored using guidance technologies such as magnetic resonance imaging
(MRI). Pre-therapy planning and real-time monitoring during treatment are
crucial to ensure that healthy tissues are not affected by the FUS beam. To
provide a cost-effective method for FUS therapy monitoring, we present a
novel technique for real-time visualization of an FUS beam using ultrasonic
backscatter. A diagnostic imaging array was used to receive backscatter
from an FUS beam interacting with tissue and the backscatter was pro-
cessed to reconstruct the intensity field of the FUS beam. The intensity field
reconstruction was then overlaid onto a co-aligned B-mode image captured
using the same imaging array to provide anatomical context. To correct for
the scattering profile of the medium, the echogenicity of the B-mode image
was used to normalize the intensity field reconstruction, allowing for robust
beam visualizations even in non-homogeneous media. The beam visualiza-
tion technique was demonstrated at a frame rate of 25-30 frames per second
in a tissue-mimicking phantom and in a rat tumor in vivo while a mock FUS
therapy was administered. To facilitate quick and cost-effective therapies,
a system for combined therapy planning, real-time beam visualization, and
low intensity FUS treatment using a single imaging array was also designed.
The therapy planning and beam monitoring capabilities of this system were
demonstrated in a tissue-mimicking phantom and in vivo. Passive cavita-
tion detection (PCD) measurements found that an imaging array can induce
stable cavitation in microbubbles and could therefore be used to administer
some low intensity FUS treatments.
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Ultrasound is widely known for its applications in biomedical imaging, where
it has become a ubiquitous technology due to its low cost, safety, and porta-
bility. While most people view biomedical ultrasound as a tool to diagnose
disease by visualizing internal structures, ultrasound can also be used to treat
disease. The ultrasound waves used for biomedical imaging have little effect
on tissue, but ultrasound can be adapted to induce therapeutic effects by
using higher pressure, focused ultrasound waves. In 1942, John G. Lynn et
al. first proposed using focused ultrasound (FUS) for non-invasive ablation
of tissue [1]. Research on FUS therapy continued throughout the 20th cen-
tury, but for many decades the technology did not receive widespread clinical
acceptance in part due to limitations in FUS therapy monitoring. Today, ad-
vancements in image-guidance and phased array technologies have helped the
medical community realize the potential of FUS.
FUS is an early-stage therapeutic modality, but it already has a broad va-
riety of clinical applications. FUS has been demonstrated to be effective at
treating many different diseases including essential tremor [2], bone metas-
tases [3], uterine fibroids [4], and prostate cancer [5]. FUS therapies are
non-invasive and can be targeted to deep regions of tissue without affecting
neighboring or intervening areas. During an FUS therapy, an ultrasound
transducer transmits bursts of sound waves that converge on a small region
of tissue, approximately the size and shape of a grain of rice. Therapeu-
tic bioeffects are induced in the treatment region through either thermal or
mechanical mechanisms. Thermal-based FUS therapies allow for surgical
ablation of tissue by using energy in the ultrasound wave to elevate tissue
temperatures. Mechanical-based FUS therapies harness mechanical stresses
produced by the ultrasound wave to induce a range of beneficial bioeffects.
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1.1 Motivation
One factor that has held back widespread clinical acceptance of FUS thera-
pies is a lack of inexpensive, real-time monitoring techniques to ensure that
the ultrasound beam is properly focused in the target region. Another lim-
iting factor is that the process of planning an FUS therapy by imaging the
treatment region and calculating the parameters needed to focus the FUS
beam can be time consuming and difficult. The motivation of this work is to
address the need for cost-effective and easy to use FUS monitoring and ther-
apy planning methods. We introduce a novel ultrasound-based technique for
the monitoring of FUS therapies. This technique uses ultrasonic backscat-
ter to visualize an FUS beam and allows for qualitative monitoring of the
ultrasound beam’s position and extent relative to surrounding tissue. This
monitoring technique only requires a diagnostic imaging array, which is al-
ready a component of many existing FUS therapy systems. This technique
is specifically designed for monitoring of mechanical-based FUS therapies,
which are growing in applications and are ill-suited for guidance using mag-
netic resonance imaging (MRI). However, the proposed method could be
applied to thermal-based FUS therapies as well. We also present a practical
system for combined therapy planning, beam monitoring, and low intensity
FUS treatment using a single diagnostic imaging array.
1.2 Literature review
1.2.1 FUS therapy monitoring
The clinical standard in FUS therapy monitoring is MRI [6, 7, 8]. MRI can
be used to visualize and quantify temperature elevations in tissue produced
by the FUS beam [9]. MRI guidance is widely used in thermal-based FUS
therapies because it can be used to track thermal bioeffects, localize the FUS
beam, and provide closed-loop control of the FUS power output [10]. Some
high intensity mechanical-based FUS therapies can also be monitored using
MRI [11]. While MRI guidance has proven to be effective, it is also expensive,
non-portable, and requires MRI-compatible ultrasound probes [12].
A number of ultrasound-based techniques have been explored for their
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potential in monitoring FUS therapies. For thermal-based therapies, ul-
trasound thermometry [13, 14] and tracking hyperechogenicity in B-mode
ultrasound images [15, 16, 17] have been proposed for therapy monitoring,
but they have not surpassed the quantitative temperature monitoring and
imaging capabilities of MRI. However, considering that tissue temperature
does not need to be monitored during many mechanical-based FUS thera-
pies, ultrasound may be better suited than MRI for monitoring this class of
therapies. B-mode ultrasound imaging can be effective at monitoring some
high intensity mechanical-based FUS therapies such as histotripsy [18, 19].
B-mode ultrasound imaging guidance works by visualizing bubbles in the fo-
cal zone that create a hyperechoic region and it is easy to implement in most
FUS systems. Passive cavitation imaging (PCI) is another ultrasound-based
monitoring technique for mechanical-based FUS therapies [20, 21, 22, 23].
PCI can be used to localize an FUS beam by mapping out acoustic emis-
sions from cavitating ultrasound contrast agents, or microbubbles, in the
focal zone of the FUS beam. PCI can provide quantitative information on
microbubble activity, which is correlated with therapeutic bioeffects [24]. Ac-
tive cavitation imaging has also been used to monitor mechanical-based FUS
therapies [25, 26, 27].
Although B-mode ultrasound imaging and PCI have been successfully used
for real-time monitoring of mechanical-based FUS therapies, there are some
limitations associated with each technique. B-mode ultrasound imaging vi-
sualizes the bubble cloud formed in the focal region during high intensity
therapy, meaning that it cannot be used for pre-therapy alignment of the
FUS beam. If the FUS beam is mis-aligned, then B-mode ultrasound imag-
ing will identify the issue only after therapy has begun and damage has
already potentially been inflicted to healthy tissue. PCI is similar in that it
can only provide feedback when microbubbles undergo cavitation and release
nonlinear emissions. This means that PCI can only be used in therapies that
involve the injection and mechanical excitation of microbubbles. PCI also
has low axial resolution because it relies on passive beamforming methods
that use relative time-of-flight information [20]. For FUS therapies that use
short duration ultrasound pulses, the axial resolution of PCI can be improved
by using absolute time-of-flight information, but this is not possible for FUS
therapies with longer therapy tone bursts [25].
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1.2.2 FUS therapy planning
Before an FUS therapy can begin, a planning stage must be carried out
in which the treatment region is identified and the FUS source is properly
aligned. The treatment region and surrounding tissue are first imaged using
a variety of different methods such as MRI [28], B-mode ultrasound imag-
ing [29], or computed tomography X-ray imaging [30]. Using these images,
a single focal location or a pattern of multiple focal locations is determined
and the FUS source is aligned to the specified location. The focal location
is selected with the goal of filling the treatment region without affecting sur-
rounding tissue. A pattern of focal locations is needed in cases when the
focal zone of the FUS source is smaller than the treatment region. After
pre-therapy imaging and alignment is completed, the FUS therapy can be-
gin. If a pattern of focal points was selected, then the FUS source must be
mechanically or electronically steered during the therapy.
Early FUS treatments relied on mechanical steering to treat regions larger
than the FUS focal zone [31, 28, 32]. Advancements in ultrasound array
technology have since made it possible to design high power phased arrays,
which can be electronically steered by applied phase delays to different ar-
ray elements [33]. Electronic steering can reduce treatment times, eliminate
the need for mechanical positioning systems, and offer a number of addi-
tional benefits. For transcranial FUS therapies, electronic steering can be
used to correct for aberrations introduced by the skull [34]. Complex focal
shapes and sonication patterns can also be designed using electronic steer-
ing [35, 36]. For example, spiral sonication patterns have been proposed for
thermal-based FUS therapies because they facilitate uniform heating of the
treatment region [37, 38]. Although high power phased arrays have many
benefits, they are expensive and their high power capabilities are unneces-
sary for low intensity FUS therapies. Many diagnostic imaging arrays (i.e.,
general purpose imaging arrays already used in clinical settings) can output
the necessary power levels required for low intensity FUS therapies [39, 40].




Chapter 2 introduces a novel FUS beam visualization technique and presents
visualizations of FUS beams in a tissue-mimicking phantom and in a rat tu-
mor in vivo. The contents of Chapter 2 were previously published in [41]
and are adapted here with permission. Chapter 3 contains a description of
a combined therapy planning, real-time monitoring, and low intensity FUS
treatment system using a diagnostic imaging array. Examples of therapy
planning in tissue-mimicking phantoms and in vivo rat tumors are presented.
The contents of Chapter 3 were previously published in [42] and are adapted




REAL-TIME FUS BEAM VISUALIZATION
USING ULTRASONIC BACKSCATTER
2.1 Introduction
The contents of this chapter were previously published in M. Thies and M. L.
Oelze, “Real-time visualization of a focused ultrasound beam using ultrasonic
backscatter,” IEEE Trans. Ultrason., Ferroelectr., Freq. Control, vol. 68,
no. 4, pp. 177–191, 2021 ( c© 2021 IEEE) [41]. The contents are adapted
here with permission.
While PCI and B-mode ultrasound imaging can be cost-effective alterna-
tives to MRI for FUS therapy monitoring, they are both limited in that they
can only be used to localize the FUS beam after therapeutic effects have
been induced in tissue. We propose a novel technique for qualitative, real-
time monitoring of the location and size of an FUS beam. This technique
does not directly monitor therapeutic effects meaning it can be used for pre-
therapy alignment and real-time monitoring during therapy. The goal of
this method is to visualize the in situ intensity field of the FUS beam using
ultrasonic backscatter from interactions between the FUS beam and tissue.
Our group first proposed the idea of visualizing the in situ intensity field
of an FUS beam in [43]. This preliminary study used a single-element FUS
source to transmit an FUS beam and a diagnostic imaging array to receive
backscattered echoes after the FUS beam was transmitted. The backscatter
was used to reconstruct the intensity field of the FUS beam, which was over-
laid onto a co-aligned B-mode image captured using the imaging array. The
position and extent of the FUS beam could then be qualitatively monitored
relative to anatomical information provided in the B-mode image. However,
this technique was not thoroughly tested in non-homogeneous media and the
reconstruction algorithms used in [43] did not allow for real-time monitoring.
Here, we build on the work in [43] and present a method for real-time
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visualization of an FUS beam using ultrasonic backscatter. A diagnostic
imaging array was used as both an FUS source and an imaging probe, but
the same technique could be carried out using separate FUS and imaging
probes. FUS beam reconstructions were achieved in non-homogeneous media
by normalizing the beam reconstructions based on the echogenicity of the co-
aligned B-mode image. Normalizing by echogenicity resulted in an increased
level of sidelobes in the FUS beam reconstructions; therefore, an adaptive
beamforming technique was used to reduce sidelobe levels and improve lateral
resolution. The FUS beam visualization technique was demonstrated at a
frame rate of 25−30 frames per second in non-homogeneous regions of a
tissue-mimicking phantom and in rat tumors in vivo.
2.2 Methods
2.2.1 Overview of FUS beam visualization method
A flow diagram describing how an FUS therapy could be monitored using the
FUS beam visualization technique is shown in Fig. 2.1. This method requires
an FUS source and a diagnostic imaging array with overlapping bandwidths.
A diagnostic imaging array can also be used as both the FUS source and the
imaging array, as was done in this study. The beam visualization is done
during the off-cycle of the FUS therapy. First, the FUS source transmits a
visualization excitation that is focused to the same location as the therapy
beam. The visualization excitation should be at a low mechanical index (MI)
to minimize therapeutic effects and should be short in duration because the
axial resolution of the FUS beam reconstruction depends on the duration of
the visualization pulse. When the FUS source transmits the visualization
excitation, the imaging array is triggered to receive backscattered echoes.
The backscatter is used to reconstruct the intensity field of the FUS beam.
The imaging array then carries out a B-mode imaging sequence to visualize
the tissue region undergoing FUS treatment. The FUS beam reconstruction
is overlaid onto the co-aligned B-mode image to allow for qualitative moni-
toring of the beam’s location and extent. Finally, the FUS source transmits
the therapy beam.
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Transmit therapy sequence with FUS 
source
Transmit beam visualization excitation 
with FUS source
Receive backscatter from visualization 
excitation with imaging array
B-mode imaging sequence with 
imaging array
Overlay FUS beam reconstruction onto 
B-mode image
Reconstruct FUS beam using 
backscatter data
Figure 2.1: Flow diagram of beam visualization method for monitoring of
an FUS therapy. Reprinted with permission ( c© 2021 IEEE).
2.2.2 Signal model
The goal of the proposed beam visualization technique is to estimate the in
situ intensity field of the FUS source. The intensity field can be calculated
using the transmitted FUS pressure field p(t, ~r), which is expressed as:
p(t, ~r) = vi(t) ∗ eT (t) ∗ hT (t, ~r), (2.1)
where ∗ denotes convolution with respect to time, vi(t) is the visualization
excitation pulse, eT (t) is the electromechanical impulse response of the FUS
source during transmission, and hT (t, ~r) is the spatial impulse response of
the FUS source during transmission [44, 45]. This model ignores the effects
of dispersive attenuation. The signal received by the imaging array after the
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FUS source transmits the visualization excitation is:
v(t, ~r) = vi(t) ∗ eT (t) ∗ hT (t, ~r) ∗ s(t, ~r) ∗ hR(t, ~r) ∗ eR(t), (2.2)
where s(t, ~r) is a scattering function that describes inhomogeneities in the
acoustic properties of the medium, hR(t, ~r) is the spatial impulse response
of the imaging array during reception, and eR(t) is the electromechanical
impulse response of the imaging array during reception. Therefore, if one
wants to estimate the transmitted FUS field p(t, ~r) using the backscattered
signal received by the imaging array v(t, ~r), then the spatial dependence of
s(t, ~r) and hR(t, ~r) must be eliminated from v(t, ~r).
The spatial dependence of the receive spatial impulse response hR(t, ~r) can
be minimized by using a beamformer with dynamic receive focusing and a
fixed f-number receive aperture. The spatial dependence of the scattering
function s(t, ~r) can be addressed by normalizing the received signal based
on the echogenicity of the medium, which is conveyed in the co-aligned B-
mode image. With these modifications, the received signal v(t, ~r) can be
approximated as:
v(t, ~r) ≈ p(t, ~r) ∗ hR(t) ∗ eR(t). (2.3)
Thus, the signal received at the imaging array v(t, ~r) provides an estimate of
the transmitted FUS pressure field p(t, ~r) after being smoothed by convolu-
tions with hR(t) and eR(t). The FUS intensity field can then be calculated
using the estimated pressure field.
2.2.3 FUS beam reconstruction
The imaging array recorded backscatter from the focused visualization pulse
at approximately four samples per wavelength. To reconstruct the in situ
FUS intensity field, the radio frequency (RF) data were first beamformed
using delay-and-sum (DAS) beamforming with generalized coherence factor
(GCF) weighting. GCF weighting is an adaptive beamforming technique that
reduces sidelobe levels and improves lateral resolution. The GCF is defined
as:








where the z-axis is imaging depth, the x-axis is along the array, s[x,z][k] is the
receive subaperture RF data after applying time delays to focus to the point
[x, z], S[x,z][k] is the discrete Fourier transform of s[x,z][k], N is the number
of channels in the receive subaperture, and M is a parameter of the GCF
(M = 2 was chosen for all results). The GCF can be thought of as a ratio of
the low frequency and DC energy of the receive aperture signal to the total
energy in the signal.
A dynamic receive subaperture with a constant f-number (f#) of 1 was
used during beamforming. Time delays τ [x, z] were calculated using the
following equation:
τ [x, z] = τF [xc] +
z +
√
z2 + (x− xc)2
c
, (2.5)
where c is the speed of sound in the medium and τF [xc] is the time delay
applied on transmit to focus the center element xc in the receive subaperture.
The output of the DAS-GCF beamformer y[x, z] was calculated as:




where w[i] is a Hanning window of length N .
The intensity field I[x, z] was found using a pulse intensity integral, which
is a method to find the intensity of an acoustic wave using measurements of





∆z|y[x, z + i]|2, (2.7)
where L is the length of the transmit pulse in samples and ∆z is the axial
sampling period of the RF data.
2.2.4 Normalization by echogenicity
The intensity field I[x, z] of the FUS beam will be affected by the scattering
properties of the medium because ultrasonic backscatter is used to recon-
struct the beam. For example, if the medium being insonified contains a
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hypoechoic region, then the FUS beam will incorrectly be displayed as being
less intense in that region. To address this, the FUS beam reconstruction
was normalized based on the echogenicity of a co-aligned B-mode image cap-
tured by the imaging array. The normalization factor amplified regions of
the FUS beam reconstruction that were within poorly scattering regions of
the medium, allowing for a more uniform visualization of the FUS beam.
The B-mode image was convolved with a 5.5 wavelengths × 7 wavelengths
moving average kernel to reduce the effect that speckle noise and small-scale
features had on the normalization procedure. A normalization factor λ[x, z]





where B[x, z] is the magnitude of the signal envelope in the smoothed B-mode
image and Bmax is the maximum value of B[x, z].
The normalization factor λ[x, z] was applied to the intensity field I[x, z] as
follows:
Inorm[x, z] = L× I[x, z]× |λ[x, z]|2, (2.9)
where L is the length of the visualization pulse in samples. The normalization
factor could also be directly applied to the beamformed data by multiplying
each point in y[x, z] by λ[x, z]. When applied to I[x, z], the factor of L was
included to account for the L samples used in Equation (2.7) and λ[x, z] was
squared because the beamformed data y[x, z] was squared in Equation (2.7)
to derive the intensity field I[x, z]. The normalization factor λ[x, z] was not
applied to points where the decibel scale B-mode image was 60 dB or more
below the maximum because it was assumed that signal from these points
was mostly noise. Finally, Inorm was compressed to decibel scale, normalized
to the maximum, and superimposed onto the co-aligned B-mode image for
display.
2.2.5 Experimental configuration
An L9-4/38 linear array (Center frequency: 5 MHz; No. elements: 128;
Ultrasonix, Richmond BC, Canada) was used as an FUS source and as an
imaging array. A Verasonics Vantage 128 Research Ultrasound System (Kirk-
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land, Wa) was used to drive the ultrasound array and acquire RF data. To
test the FUS beam visualization technique, data were collected in a tissue-
mimicking phantom (Supertech Model ATS 539; Elkhart, IN), a rat tumor
in vivo, and a tank of degassed water containing a wire target.
The excitation sequence used for FUS beam visualization contained an
FUS visualization pulse, a mock FUS therapy pulse, and a B-mode imaging
sequence. The excitation sequence started with the imaging array transmit-
ting a 2-cycle focused visualization pulse at 5 MHz, which was focused to a
target point in the medium. Backscatter from this focused visualization pulse
was used to reconstruct the FUS intensity field. The imaging array then car-
ried out a coherent plane wave compounding B-mode imaging sequence using
a series of 11 steered plane waves (−18◦ to 18◦), each consisting of a 2-cycle
tone burst at 5 MHz [46]. Finally, the imaging array transmitted a 25-cycle
tone burst at 5 MHz to simulate an FUS therapy beam. This mock therapy
pulse was focused to the same location as the focused visualization pulse. It
was referred to as a mock therapy pulse because it used similar parameters as
those typically used in low intensity mechanical-based FUS treatments, but
no therapeutic effects were induced because no microbubbles were used. The
focused visualization pulse and mock therapy pulse had an MI of 0.52 (Ele-
ment diameter: 0.04 mm; Precision Acoustics, Dorchester UK) in degassed
water. In an actual FUS therapy, the therapy pulse would have a higher MI
than the visualization pulse. For the reconstructions in a hypoechoic (−15
dB) contrast target, the focused visualization pulse had an MI of 0.89 be-
cause higher pressure values were required for adequate visualization of the
beam within the poorly scattering contrast target.
The DAS-GCF beamformer and pulse intensity integration were imple-
mented on a GPU (NVIDIA Quadro P2000, Santa Clara, CA) using the
parallel programming platform CUDA. The normalization by echogenicity
procedure was carried out on the GPU using GPU-enabled functions in MAT-
LAB (MathWorks, Natwick, MA). The built-in Verasonics beamformer was




The animal protocol was approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Illinois at Urbana-Champaign.
Tumors were induced in female F344 rats by injecting MAT tumor cells
(100 µL containing 5× 102− 1× 105 cells) bilaterally into the mammary fat
pad. Once the tumors reached 0.5 to 1.5 cm in diameter, the animal was
anesthetized with isoflurane and imaged using the FUS beam visualization
technique. A bucket of degassed water with a plastic wrap bottom was placed
over the tumor to create an adequate standoff distance between the imaging
array and the tumor. Mineral oil was used to couple the plastic wrap to the
animal’s skin.
2.2.7 Performance metrics
To confirm that the proposed method provided an accurate reconstruction
of the FUS intensity field, the imaging array was used to transmit a 2-cycle
focused visualization pulse at 5 MHz and the intensity field was measured
in degassed water by moving a hydrophone through the beam field using a
mechanical positioning system (Daedal, Harrison City, Pa) with a step size
of 200 µm. The −3 dB transmit beamwidth and depth of field of the FUS
beam were measured using the hydrophone-determined transmit FUS field.
These were compared to the −6 dB transmit-receive beamwidth and depth of
field of the FUS beam determined using the proposed method with ultrasonic
backscatter from a homogeneous region of a tissue-mimicking phantom. The
experimental measurements were also compared to the theoretical −3 dB
transmit beamwidth and depth of field of a spherical focused source assuming
a continuous wave excitation, which are approximated as:




where λ is the wavelength of the excitation and f# is the f-number of the
FUS source [47].
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The echogenicity of the medium affected the FUS beam visualization found
using ultrasonic backscatter. To quantify the effect that the echogenicity
of the medium had on the FUS beam reconstructions, mean square error
(MSE) values between baseline FUS beam reconstructions measured in ho-
mogeneous regions of a phantom and FUS beam reconstructions measured in
different non-homogeneous regions were calculated. The baseline FUS beam
reconstructions were measured in homogeneous regions of a phantom with
the same excitation sequence parameters as the reconstructions measured in
non-homogeneous regions. Before MSE values were calculated, the beam re-
constructions were clipped to [−60 dB, 0 dB] because the clipped fields more
accurately reflected the information displayed to a user. The FUS beam
reconstructions were also filtered with a 5.5 wavelengths × 5 wavelengths
median filter to reduce the effect of speckle noise. The MSE values before
and after normalizing by echogenicity were calculated to evaluate the efficacy
of normalization. MSE values were computed between each reconstruction in
a non-homogeneous region and five different baseline homogeneous regions,
and the five values were averaged to further minimize the effect of speckle
variance. The average MSE value between the five baseline homogeneous re-
gions was also calculated to determine the error caused by speckle variance.
2.3 Results
To evaluate the accuracy of the proposed beam visualization technique, the
FUS intensity field of the L9-4 imaging array as measured using a needle
hydrophone in degassed water (Fig. 2.2a) and the intensity field as measured
using ultrasonic backscatter with the proposed method in a homogeneous
tissue-mimicking phantom (Fig. 2.2b) were compared. The estimated −3
dB transmit (equivalent to −6 dB transmit-receive) beamwidth and depth
of field of the hydrophone-determined FUS intensity field were 0.35 mm and
2.05 mm, respectively. The theoretical −3 dB transmit beamwidth and depth
of field for the FUS beam (Center frequency: 5 MHz; Focal depth: 30 mm)
were 0.23 mm and 1.20 mm, respectively. The estimated −6 dB transmit-
receive beamwidth and depth of field of the backscatter-determined intensity
field were 0.91 mm and 2.83 mm. However, it was difficult to estimate
these parameters for the backscatter-determined FUS intensity field because
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(a) (b)
Figure 2.2: Intensity field of an FUS beam targeted to 30 mm using all 128
elements of L9-4 imaging array. (a) Hydrophone determined intensity field.
(b) Ultrasonic backscatter determined intensity field (blue/yellow) overlaid
onto co-aligned B-mode image (grayscale). The intensity field was
reconstructed using backscatter from a homogeneous tissue-mimicking
phantom.
speckle variance degraded the beam reconstruction.
The effects of the echogenicity of the medium on the FUS beam visual-
ization method were studied by capturing beam reconstructions in various
non-homogeneous regions of a tissue-mimicking phantom. Beam visualiza-
tions of an FUS beam targeted to a hyperechoic (+15 dB) contrast target
are shown in Fig. 2.3. Before normalizing by echogenicity, the FUS beam
was shown as having higher intensity within the hyperechoic contrast tar-
get because more backscatter was received from this region compared to the
surrounding medium (Fig. 2.3a). After normalization, the FUS beam recon-
struction was more representative of the actual intensity field because regions
outside of the contrast target were amplified (Fig. 2.3b).
Beam reconstructions were captured of an FUS beam targeted to a hypoe-
choic (−15 dB) contrast target in a tissue-mimicking phantom (Fig. 2.4).
Before normalizing by echogenicity, the beam was reconstructed as having a
low intensity within the hypoechoic contrast target because little backscat-
ter was received from this area (Fig. 2.4a). Normalization amplified the




Figure 2.3: Beam visualizations of an FUS beam targeting a hyperechoic
(+15 dB) contrast target in a tissue-mimicking phantom. The FUS beam
was targeted to 35 mm using all 128 elements. (a) Before normalizing by
echogenicity. (b) After normalizing by echogenicity.
for a more uniform visualization of the FUS beam (Fig. 2.4b). A higher MI
was required to produce an adequate reconstruction of the FUS beam in Fig.




Figure 2.4: Beam visualizations of an FUS beam targeting a hypoechoic
(−15 dB) contrast target in a tissue-mimicking phantom. The FUS beam
was targeted to 40 mm using all 128 elements. (a) Before normalizing by
echogenicity. (b) After normalizing by echogenicity.
was deep in the phantom and hypoechoic.
The effects of normalizing by echogenicity were studied for an FUS beam
targeted to a line of point targets in a tissue-mimicking phantom (Fig. 2.5).
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Before normalization, it was difficult to visualize the FUS beam because
the strongly scattering point targets dominated the dynamic range used for
display (Fig. 2.5a). Normalization facilitated easier visualization of the FUS
beam by amplifying regions of the beam reconstruction outside of the point
targets (Fig. 2.5b). The regions laterally adjacent to the point targets were
darkened due to an artifact introduced by the GCF [48, 49]. The signal from
these regions contains a large amount of incoherent sidelobe signal from the
point targets, which results in the GCF attenuating the beamformed signal.
To investigate the impact of normalizing by echogenicity on the overall
fidelity of the beam visualizations, reconstructions of an FUS beam focused
on a wire target in degassed water were captured (Fig. 2.6). While normal-
ization was required to produce satisfactory beam reconstructions in non-
homogeneous regions, it also resulted in an increase in sidelobe levels. FUS
beam reconstructions produced using conventional DAS beamforming be-
fore normalization (Fig. 2.6a) and after normalization (Fig. 2.6b) were
compared. Sidelobe levels substantially increased after normalization was
applied. FUS beam reconstructions produced using DAS-GCF beamform-
ing had lower sidelobe levels than the DAS reconstructions. Furthermore,
the DAS-GCF reconstruction without normalization (Fig. 2.6c) had lower
sidelobe levels than the DAS-GCF reconstruction with normalization (Fig.
2.6d) due to the increase in sidelobe levels caused by normalization. The
normalization factor was calculated using a co-aligned B-mode image, which
resolved the wire target with low sidelobe levels because plane wave coherent
compounding with multiple steered plane waves was used. The FUS beam
reconstruction did not resolve the wire target with low sidelobe levels because
a single focused transmit was used. Therefore, the regions corresponding to
sidelobes in the FUS beam reconstruction were relatively dark in the B-mode
image and were amplified by the normalization factor. A comparison of the
lateral profile of the FUS intensity fields at the depth of the wire target for
the four configurations displayed in Fig. 2.6 reveals that DAS-GCF beam-
forming was necessary to reduce sidelobes to an acceptable level (Fig. 2.7).
Sidelobe levels increased by about 15 dB when normalization by echogenicity
was applied. The lower threshold of −60 dB for was turned off for the wire
target reconstructions to characterize the worst-case of sidelobe amplification
due to normalization.




Figure 2.5: Beam visualizations of an FUS beam targeting a line of point
targets in a tissue-mimicking phantom. The FUS beam was targeted to 29
mm using all 128 elements. (a) Before normalizing by echogenicity. (b)
After normalizing by echogenicity.
the proposed beam visualization method would be suitable for in vivo FUS
therapies (Fig. 2.8). Before normalizing by echogenicity, it is difficult to




Figure 2.6: FUS intensity fields measured using a wire target in degassed
water. The FUS beam was targeted to 27 mm using all 128 elements. The
lower threshold of −60 dB for applying normalization was turned off for
these images allowing the normalization factor to be applied to the entire
FUS intensity field. (a) DAS beamforming without normalization. (b) DAS
beamforming with normalization. (c) DAS-GCF beamforming without
normalization. (d) DAS-GCF beamforming with normalization.
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Figure 2.7: Comparison of a lateral slice at the depth of the wire target of
the FUS intensity fields shown in Fig. 2.6.
(Fig. 2.8a). After normalization, the FUS beam can be clearly localized
within the context of the surrounding tissue (Fig. 2.8b). Real-time FUS
beam visualization was achieved in vivo at a frame rate of 25-30 frames per
second.
To quantify how the scattering properties of the medium affected beam vi-
sualization, MSE values were calculated between FUS beam reconstructions
in non-homogeneous regions of a phantom and in baseline reconstructions
in homogeneous regions (Table 2.1). The results reported in Table 2.1 are
an average of five MSE values calculated using five different baseline recon-
structions compared to each non-homogeneous reconstruction. The average
MSE value between the five homogeneous regions was found to be 14.70 after
normalization, which represents the error caused only by speckle variation.
For the non-homogeneous regions, normalizing by echogenicity reduced the
MSE by 27.46, on average, indicating that it helped correct for changes in





Figure 2.8: Beam visualizations of an FUS beam targeting a rat tumor in
vivo. The FUS beam was targeted to 27 mm using all 128 elements. (a)
Before normalizing by echogenicity. (b) After normalizing by echogenicity.
2.4 Discussion
We have presented a novel technique for real-time visualization of an FUS
beam using ultrasonic backscatter from the FUS beam interacting with tis-
sue. This technique can provide continuous monitoring of the position and
extent of an FUS beam relative to the surrounding medium by superimposing
an intensity field reconstruction of the FUS beam onto a co-aligned B-mode
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Table 2.1: MSE values for FUS beam reconstructions from different regions
of phantom compared to baseline reconstructions.
Reconstruction Original Normalized
Baseline 14.55 14.70
Hyperechoic contrast target (+6 dB) 13.88 11.48
Hyperechoic contrast target (+15 dB) 78.39 19.74
Hypoechoic contrast target (−6 dB) 21.01 21.97
Hypoechoic contrast target (−15 dB) 33.76 26.05
Point targets 33.76 26.05
image. We expect that this technique could be valuable for monitoring FUS
therapies because it is vital to have real-time information on the orienta-
tion of the FUS beam during treatment to ensure that healthy tissues are
not damaged. While the motivation of this work was to address the need
for cost-effective monitoring techniques for mechanical-based FUS therapies,
the proposed method could also be used to monitor thermal-based thera-
pies. FUS beam visualization using ultrasonic backscatter could be used in
combination with MRI guidance during thermal-based treatments to provide
additional redundancy and verification of either method.
To verify the proposed method, an FUS beam reconstruction produced
using backscatter from a homogeneous phantom was compared to the inten-
sity field measured using a needle-hydrophone (Fig. 2.2). The location and
size of the beam in the FUS beam visualization corresponded well with those
measured using a needle-hydrophone. However, the beam width and depth
of field of the backscatter-determined reconstruction did not align well with
the theoretical values or the hydrophone-determined measurements. It was
expected that there would be some differences between the FUS intensity
fields measured using the two methods because the point spread function of
the backscatter-determined reconstruction involved properties of the imaging
array on receive and transmit, while the hydrophone measurements were re-
ceive only. Furthermore, the −6 dB transmit-receive beamwidth and depth of
field were difficult to estimate in the beam visualization due to the presence of
speckle. Frequency compounding was tested to reduce speckle in the beam re-
constructions, but it produced unsatisfactory reconstructions due to a loss of
axial resolution. Although the proposed method cannot accurately measure
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the beamwidth or depth of field of an FUS beam, it does provide real-time
information on the position of the beam which is sufficient for qualitative
monitoring of FUS therapies. Spatial compounding using multiple transmit
beams could be tested as in [43] to reduce speckle noise, but this was not
explored in this work because real-time qualitative beam visualization was
the main goal.
FUS beam reconstructions were demonstrated in various non-homogeneous
regions of a tissue-mimicking phantom by normalizing the reconstructions
based on the echogenicity of co-aligned B-mode images (Fig. 2.3, Fig. 2.4,
Fig. 2.5). The scattering profile of the medium being insonified affected
the reconstructed intensity fields because the reconstructions were produced
using ultrasonic backscatter. The co-aligned B-mode images visualized the
scattering profile of the medium, meaning that they could be used to nor-
malize the beam reconstructions. Although a single ultrasound probe was
used in this work, normalizing by echogenicity could also be used with a sep-
arate imaging array and FUS source provided the transducers are properly
registered.
Although normalization was required to produce adequate beam visual-
izations in non-homogeneous regions, it also increased sidelobe levels by up
to 15 dB (Fig. 2.6 and Fig. 2.7). This reduced the tolerance for allowable
sidelobes during beamformation. Thus, DAS-GCF was used to reduce side-
lobes in the beam reconstructions. GCF weighting was selected over other
adaptive beamforming methods because it is computationally inexpensive,
allowing for real-time beam visualization. However, GCF weighting will in-
troduce dropout artifacts such as those shown in Fig. 2.5. Furthermore,
GCF weighting will attenuate signals that suffer from focusing errors, mean-
ing that it may attenuate poorly focused signals that should appear in the
beam visualizations. For example, reflections of the FUS beam from tissue
interfaces will be subject to focusing errors because they occur later in time
than from the depth they actually originate.
On average, normalizing by echogenicity decreased the MSE between base-
line beam reconstructions and reconstructions in non-homogeneous regions
of a phantom (Table 2.1), suggesting that normalization reduced the effects
of the scattering properties of the medium on the beam visualizations. How-
ever, there are limitations with using the MSE to quantify differences between
beam reconstructions from different regions of a phantom. First, speckle vari-
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ance will contribute to the MSE. Even after reducing speckle in the beam
reconstructions using a median filter, the baseline MSE caused by speckle
variance was 14.70. Second, a beam reconstruction in a homogeneous re-
gion is not a true baseline for a reconstruction in a non-homogeneous region
because the scattering profile will affect the actual FUS intensity field. For
example, reflective interfaces in a non-homogeneous region could cause reflec-
tions of the FUS beam that do not appear in reconstructions from a baseline
homogeneous region.
A single diagnostic imaging array was used as both an FUS source and
an imaging probe for FUS beam visualization. Most ultrasound therapy
monitoring techniques use an imaging array and a separate high power FUS
source. The benefits of using a diagnostic imaging array as an FUS source
are discussed in Chapter 3. However, the proposed method does not re-
quire the use of a diagnostic imaging array as the FUS source. A more
conventional FUS source can be used with a secondary imaging array to pas-
sively receive backscatter provided that the transducers have an overlapping
bandwidth. A high bandwidth FUS source is ideal for beam visualization
because the axial resolution of the FUS beam reconstruction depends on the
duration of the focused visualization pulse transmitted by the FUS source.
However, high power FUS sources are often narrowband in order to more
efficiently produce ultrasonic power. The proposed technique could also be
implemented using a dual-mode FUS and imaging array, which have success-
fully been used for real-time B-mode imaging and ultrasound thermometry
during therapy [50, 51]. Many FUS therapy systems use a low frequency, nar-
row bandwidth FUS source with a high frequency imaging array for B-mode
imaging. For these systems, it is possible that the proposed method could
be used with the imaging array passively receiving harmonics of the focused
visualization pulse, similar to tissue harmonic imaging [52]. However, this
would likely require increasing the MI of the focused visualization pulse to
generate sufficient harmonics and it is not clear if the harmonic visualization
beam would be representative of the FUS therapy beam at the fundamental
frequency.
The proposed method assumes that the low MI, short duration visualiza-
tion pulse used to monitor the FUS beam has a similar acoustic field to the
therapy pulse, which will typically have a higher MI and longer duration. For
therapies where high power therapy pulses are used such as thermal ablation
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and histotripsy, the therapy beam will propagate in a nonlinear manner and
the assumption that the linear acoustic field of the visualization beam is rep-
resentative of the nonlinear acoustic field of the therapy beam may break
down. For example, the axial profiles of low amplitude pulses have been
shown to differ significantly from the axial profiles at higher amplitudes [53].
Another limitation is that the short duration visualization pulse will have
different frequency content than the longer duration therapy pulse. The vi-
sualization beam is expected to have a wider beamwidth than the therapy
beam because short duration pulses use a wider bandwidth than long dura-
tion pulses.
Compared to therapy monitoring with B-mode imaging, the proposed
method is favorable because it can be used to localize the FUS beam be-
fore therapeutic effects are induced. B-mode imaging guidance is effective
for histotripsy because it allows one to observe the formation of a hyper-
echoic cavity in the focal region during treatment [18]. However, this hy-
perechoic cavity signifies that tissue fractionation is being induced, meaning
that B-mode imaging can recognize a mis-aligned FUS beam only after tis-
sue damage has already occurred. FUS beam visualization using ultrasonic
backscatter does not require any therapeutic effects to localize the beam.
Therefore, it could be used to confirm the beam is correctly targeted before
treatment is initiated without damaging healthy tissue.
The proposed beam visualization method is similar to PCI in that an
imaging array is used to receive signals produced by an FUS beam, but vi-
sualization using ultrasonic backscatter is distinct from PCI in a number of
ways. PCI resolves signals from nonlinear microbubble activity caused by in-
teractions between the FUS therapy beam and microbubbles. The proposed
method resolves backscatter created by interactions between the FUS visu-
alization beam and tissue at the fundamental frequency of the FUS source.
PCI can use relative time-of-flight information [20] or absolute time-of-flight
information [54, 25] during beamforming. Approaches that use relative time-
of-flight typically have poor axial resolution because the axial resolution de-
pends on the diffraction pattern of the passive imaging array [20]. For ap-
proaches that use absolute time-of-flight, the axial resolution of the image
depends on the duration of the FUS therapy pulse. Therefore, absolute time-
of-flight PCI will have poor axial resolution for therapies where long therapy
pulses are used. With the proposed method, the imaging resolution is decou-
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pled from therapy parameters because separate therapy and beam visualiza-
tion pulses are used. One benefit of PCI is that it can be used to both localize
the FUS beam and quantitatively monitor therapeutic bioeffects [24]. Beam
visualization using ultrasonic backscatter can only qualitatively monitor the
position and size of the FUS beam. For therapies where PCI is required for
quantitative monitoring of bioeffects, the proposed method could be used for
pre-therapy alignment of the FUS beam and for visualization of the beam at
the fundamental frequency during treatment.
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CHAPTER 3
LOW INTENSITY FUS THERAPY
SYSTEM USING A DIAGNOSTIC
IMAGING ARRAY
3.1 Introduction
The contents of this chapter were previously published in M. Thies and M.
L. Oelze,“Planning and real-time monitoring of low intensity focused ultra-
sound therapies using a diagnostic imaging array,” in Medical Imaging 2021:
Ultrasonic Imaging and Tomography, vol. 11602, International Society for
Optics and Photonics, 2021, pp. 116020I. The contents are adapted here
with permission.
Clinical FUS therapy systems such as the Philips [55] and Insightec sys-
tems [56, 57] use a high power phased array as an FUS source for treatment
and MRI for therapy planning and monitoring. Whereas these systems have
proven to be effective and safe, they are also expensive and non-portable. As
discussed in Chapter 2, beam visualization using ultrasonic backscatter or
PCI could be a cost-effective alternative to MRI for some mechanical-based
FUS therapies. However, the high power phased arrays used in clinical ther-
apy systems are also expensive due to the engineering challenges associated
with their design [33].
High power phased arrays are required for FUS therapies such as thermal-
based treatments and histotripsy because high intensity FUS pulses are used.
However, a new class of FUS therapies has been recently emerging. These
therapies use low intensity FUS pulses typically in combination with the in-
jection of microbubbles to stimulate mechanical bioeffects in tissue. Some
examples of low intensity mechanical-based FUS therapies are opening of the
blood-brain barrier [58], sensitization of tumors to radiation therapy [59], tar-
geted drug delivery [60], and neuromodulation [61]. For many of these thera-
pies, high power FUS sources are not required, and diagnostic imaging arrays
can output the required pressure levels. In vivo opening of the blood-brain
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barrier with simultaneous monitoring was recently demonstrated using a di-
agnostic imaging array [39]. The use of an imaging array as an FUS source
facilitates easy beam steering and image guidance during therapy. Further-
more, an FUS therapy system could be more cost-effective and simplified
if both treatment and monitoring could be done using a single ultrasound
probe.
In this chapter, we describe a system for low intensity mechanical-based
FUS therapies that enables straightforward therapy planning and real-time
monitoring using a single diagnostic imaging array. The use of a single ultra-
sound probe for planning, monitoring, and treatment means that alignment
between probes or registration between different imaging modalities was not
required. First, the imaging array acquired a B-mode image that was used
to identify the treatment region. The FUS therapy beam was then elec-
tronically steered throughout the treatment region. The therapy beam was
monitored in real time using ultrasonic backscatter as described in Chapter
2. The combined therapy planning and monitoring system was tested in a
tissue-mimicking phantom and in a rat tumor in vivo. An FUS therapy was
not administered using this system, but the excitation sequence contained
a mock therapy tone burst to mimic an actual FUS therapy. To test if a
diagnostic imaging array can achieve the pressure levels needed for low in-
tensity FUS therapies, the imaging array was used to insonify a population of




An overview of the low intensity FUS therapy system is shown in Fig. 3.1.
The system was developed using a Verasonics Vantage 128 Research Ultra-
sound System and an Ultrasonix L9-4/38 array probe. First, the imaging
array was aligned to the treatment region using real-time B-mode imaging
created in the MATLAB environment by the Verasonics system. The treat-
ment region was then manually segmented from a B-mode image by tracing
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Figure 3.1: Flow diagram of FUS therapy planning and monitoring method
using a single diagnostic imaging array.
the arbitrarily shaped, closed treatment region. Once treatment was initi-
ated, the imaging array traversed through the focal point grid by focusing
the therapy beam to each point in the grid. The FUS beam was monitored
in real time using the beam visualization method described in Chapter 2.
Briefly, before transmitting the FUS therapy sequence, the imaging array
transmitted a short, low power visualization pulse, which was focused to the
same location as the FUS therapy pulse. Backscatter from the visualization
pulse was received by the imaging array and used to reconstruct the intensity
field of the FUS beam.
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3.2.2 Therapy planning
Given a manually segmented treatment region, a bounding box was first
calculated to enclose the arbitrarily shaped area. A grid of focal points was
created to fill the bounding box with a step size determined by the estimated
beamwidth and depth of field of the FUS beam. The lateral step size ∆x
and axial step size ∆z of the focal point grid were defined as:
∆x = R−3dB (3.1)
and
∆z = 0.5DOF−3dB, (3.2)
where R−3dB and DOF−3dB are the theoretical −3 dB transmit beamwidth
and depth of field, respectively, as defined in Equation (2.10) and Equation
(2.11), the x-axis is the lateral direction along the array, and the z-axis is
the axial direction perpendicular to the array. The f# of the FUS beam was
dynamically calculated by taking the ratio of the depth of the segmented
region’s center point to the diameter of the transmit aperture. To reduce the
overlap between adjacent rows of focal points, every other row of focal points
was offset from the left edge of the bounding box by 0.5∆x in the positive x
direction. Finally, all focal points in the bounding box grid that did not fall
within the segmented region were discarded, leaving a grid of focal points
that filled the treatment region.
3.2.3 Experimental configuration
The Ultrasonix L9-4/38 array probe was driven by a Verasonics Vantage
128 Research Ultrasound System. To demonstrate the therapy planning
and beam monitoring system, data were collected from the ATS 539 tissue-
mimicking phantom and a rat tumor in vivo. The animal experiments were
carried out using the same protocol described in Chapter 2. The excitation
sequence consisted of a therapy planning stage and a treatment with moni-
toring stage. The excitation sequence was modeled after the sequence used
for a radiosensitization FUS therapy [59]. This low intensity, mechanical-
based FUS therapy sensitizes tumors to radiation therapy by insonifying the
tumors after a systemic injection of microbubbles. However, no therapeutic
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effects were induced in this study because microbubbles were not used in the
phantom or in vivo experiments. Therefore, the therapy sequence is referred
to as a mock therapy. For therapy planning, the imaging array transmitted
11 steered plane waves (−18◦ to 18◦) and a B-mode image was created using
coherent plane wave compounding [46]. For the treatment with monitoring
stage, the imaging array imaged the treatment region via B-mode and visu-
alized the FUS beam during the off-cycle of the FUS therapy. Each mock
treatment window lasted for 50 ms and each imaging window lasted for 2
s. A long duration imaging window was used because it would allow for
microbubbles to refresh in the treatment region if an actual low intensity
mechanical-based FUS therapy was being administered. First, the imaging
array acquired a B-mode image using the same coherent plane wave com-
pounding sequence that was used for therapy planning. The imaging array
then transmitted a 2-cycle focused visualization pulse at 5 MHz focused to
a focal point in the grid and the backscattered echoes were processed to vi-
sualize the FUS beam. The focused visualization pulse had an MI of 0.52.
This imaging sequence repeated for 2 s, which was the off-cycle between each
treatment window. Next, the imaging array transmitted a 160-cycle ther-
apy pulse at 5 MHz. The mock therapy pulse was repeatedly transmitted
at a pulse repetition frequency of 3 kHz for 50 ms. The mock therapy pulse
was focused to the same location as the focused visualization pulse and had
an MI of 0.81. After one treatment and imaging window, the focal point
would be updated to the next point in the grid. This sequence of interleaved
monitoring and treatment was repeated for all locations in the focal point
grid. All MI values were determined using a membrane hydrophone (Element
diameter: 0.04 mm; Precision Acoustics, Dorchester UK) in degassed water.
3.2.4 Passive cavitation detection
To test if a diagnostic imaging array can achieve the pressure levels required
for low intensity mechanical-based FUS therapies, a passive cavitation detec-
tion (PCD) experiment was done. The L9-4/38 array was used to insonify a
population of microbubbles in degassed water while a single-element trans-
ducer (Center frequency: 3 MHz, Focal length: 0.75 inches) passively received
acoustic emissions. The transducers were first orientated perpendicular to
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each other and a wire target was used to align the focal zones. An acoustic
absorber was placed at the bottom of the water tank to minimize reflections
and a mixer was used to circulate the water and microbubbles. Control
measurements were first collected by using the imaging array to apply an
FUS beam to degassed water without microbubbles and passively detect-
ing acoustic signals with the single-element transducer. Measurements were
taken using a 25-cycle FUS beam with 13 MI values varying from 0.15 to
1.17 and a 160-cycle FUS beam with 9 MI values varying from 0.15 to 0.89.
Definity microbubbles (5 mL) were then added to the water using a 25-gauge
needle. The microbubbles were activated using a Vialmix activation device
4 days before the experiment and were manually re-agitated immediately
before being added to the water. PCD measurements were collected across
varying MI values immediately after injection of the microbubbles. The FUS
beam consisted of a 5 MHz tone burst at a pulse repetition frequency of 333
Hz. After each transmit event, the single-element transducer was triggered
to record RF data using a pulser/receiver (Panametrics 5800PR, Olympus,
WA, USA) at a sample rate of 250 MHz. For each MI value tested, 100
frames of A-mode data were collected using the single-element transducer.
The FUS beam was turned off for at least 5 s in between data acquisition
windows to allow for the microbubbles to refresh in the focal region.
Slow-time spectrograms were created from the PCD data to visualize the
frequency content of the acoustic emissions over the data acquisition window.
Each vertical slice of the slow-time spectrograms contained the spectrum of
a single frame of A-mode data. The plots were referred to as slow-time
spectrograms because the horizontal axis corresponded to frame number, as
opposed to conventional spectrograms which have time on the horizontal axis.
Each frame of A-mode data was trimmed to a 5000 sample window around
the focal region of the transducers and a Hamming window was applied. The
fast Fourier transform (FFT) of the frame was then calculated without any
overlap between adjacent frames.
To estimate the amount of cavitation caused by the FUS beam, cavita-
tion doses were calculated from the PCD data [62]. The stable cavitation
dose is a measure of stable cavitation, or the moderate oscillation of mi-
crobubbles without collapsing, and is related to the energy in harmonic and
sub-harmonic bands of the PCD data [63]. The A-mode data were trimmed
to a 5000 sample window around the focus and the FFT of each frame was
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calculated. The root mean square (RMS) of a narrow band of the spectrum
around the sub-harmonic ([2.4 MHz, 2.6 MHz]) was calculated and the RMS
values for the 100 frames of A-mode data were plotted over time. Each RMS
measurement was separated by 3 ms because the pulse repetition frequency
was 333 Hz. The stable cavitation dose was defined as the area under the
RMS vs. time curve. The inertial cavitation dose is a measure of inertial
cavitation, or the rapid oscillation and collapse of microbubbles, and is re-
lated to broadband noise and the energy in inharmonic bands (i.e., not a
subharmonic, harmonic, or ultraharmonic band) of the PCD data [62]. The
inertial cavitation dose was calculated using a similar procedure as the sta-
ble cavitation dose except the average RMS of three inharmonic bands ([1.9
MHz, 2.1 MHz], [3.6 MHz, 3.8 MHz], and [4.2 MHz, 4.4 MHz]) was used.
3.3 Results
The therapy planning and beam monitoring system was tested in a tissue-
mimicking phantom. After aligning the imaging array to the target region
using B-mode imaging, a B-mode image was captured for segmentation of the
treatment region (Fig. 3.2a). The target region was then manually segmented
by the user and a grid of focal points was calculated to fill the selected area
(Fig. 3.2b). The focal points were not evenly spaced laterally because the
focal points were calculated using a discrete grid, leading to small rounding
errors. Finally, the FUS therapy beam was steered through all points in the
focal point grid and the FUS beam was visualized in real-time between mock
treatment periods (Fig. 3.2c).
The therapy planning and beam monitoring system was tested in a rat
tumor in vivo. The imaging array was aligned to the tumor using B-mode
imaging (Fig. 3.3a). The tumor was then manually segmented from a B-
mode image (Fig. 3.3a). Once mock treatment was initiated, the FUS ther-
apy beam was steered through the focal point grid and the FUS beam was
monitored between mock treatment periods (Fig. 3.3a).
Control PCD measurements were collected while applying an FUS beam
(160-cycle tone burst) to degassed water. To determine if a diagnostic imag-
ing array can achieve the pressure levels required for low intensity mechanical-
based FUS therapies, PCD measurements were then captured while applying
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the same FUS beam to a population of microbubbles. Slow-time spectro-
grams were created to study the frequency content of the PCD signals over
time (Fig. 3.4 and Fig. 3.5). As the MI of the FUS beam increased, there are
no visible changes in the control measurements and there is a clear increase
in the energy at the fundamental (5 MHz) and subharmonic (2.5 MHz) fre-
quencies for the microbubble measurements. An increase in signal energy
around the subharmonic band is one indicator of stable cavitation.
Cavitation doses were calculated using the PCD data to quantify the cav-
itation activity. When microbubbles were present, an increase in the sta-
ble cavitation dose was observed as the MI values of both the 25-cycle and
160-cycle FUS beams were increased (Fig. 3.6a). A slight increase in the
inertial cavitation dose was observed for the 160-cycle FUS beam applied to
microbubbles, while a large increase occurred for the 25-cycle FUS beam ap-
plied to microbubbles (Fig. 3.6b). For the control measurements, no change
in either cavitation dose was observed as the MI values of the FUS beams
were increased. The 25-cycle FUS beam was driven at higher MI values be-
cause the lower pulse length posed less risk of damaging the imaging array.
3.4 Discussion
In this chapter, a system for combined therapy planning, real-time beam
visualization, and low intensity FUS treatment was presented. The system
was demonstrated in a tissue-mimicking phantom (Fig. 3.2) and in a rat
tumor in vivo (Fig. 3.3) while a mock FUS treatment was administered.
PCD data were collected while an imaging array applied an FUS beam to a
population of microbubbles in order to determine if an imaging array could
administer low intensity FUS treatment. By studying the frequency content
of the PCD measurements and calculating cavitation doses, it was determined
that a diagnostic imaging array can induce stable cavitation in microbubbles
(Fig. 3.4, Fig. 3.5, and Fig. 3.6).
Segmenting a pre-therapy image to identify a treatment region and calcu-
late a sonication pattern is a well-established feature of many FUS therapy
systems. The novelty of this work is that a widely available type of ultra-
sound probe was used to carry out all parts of an FUS therapy. Using a
single imaging array eliminates the need for registration between different
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ultrasound probes or imaging modalities and reduces the FUS therapy dura-
tion. One limitation of this study was that an optimal spacing of the focal
point grid was not derived. The focal point grid was selected to uniformly
fill the treatment region based on the FUS beam dimensions, but a more effi-
cient or effective grid design could be possible with further characterization.
For example, spiral focal point patterns have been proposed as the optimal
sonication pattern for thermal-based treatments [37, 38].
The proposed system relies on qualitative monitoring of the FUS beam’s
location and extent during treatment. For FUS therapies where quantita-
tive monitoring of tissue temperature or cavitation activity is necessary, a
secondary ultrasound probe or imaging modality such as MR thermometry
may be required. When choosing an imaging array to use with the proposed
system, there is a trade-off between optimizing image resolution for therapy
monitoring and optimizing the FUS treatment itself. A high frequency imag-
ing array will provide superior image resolution, but must transmit higher
pressure levels to achieve a given MI when compared to a low frequency
imaging array. Furthermore, high frequency FUS beams will be attenuated
more when treating deep tissues due to frequency-dependent attenuation.
This means that high frequency arrays may be more prone to damage when
used for low intensity FUS treatment. Ideally, a 2-dimensional (2D) imaging
array should be used with this system, to allow for treatment of a 3D region
of tissue by manually segmenting multiple image slices along the elevational
plane. Mechanical scanning in the elevational plane would be required to
treat a 3D volume using a 1D imaging array.
Because diagnostic imaging arrays are not designed for high power use,
this system is limited to low intensity FUS therapies. An in vivo low in-
tensity FUS therapy using a diagnostic imaging array was not performed in
this work, but membrane hydrophone measurements and a PCD experiment
have verified that the imaging array can achieve the pressure levels required
for many low intensity FUS therapies. Low intensity FUS therapies can in-
duce therapeutic effects at a mechanical index around 0.8 [59, 58], which was
achieved in this study without issue. Care must be taken when using an imag-
ing array to carry out an FUS therapy to ensure that the transducer is not
damaged. The mechanical index that a diagnostic imaging array can safely
achieve will depend on the center frequency of the transducer, the length of
the treatment pulse, and the pulse repetition frequency of the treatment.
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During the PCD experiment, cavitation emissions were passively detected
by a single-element transducer while an imaging array was used to apply an
FUS beam to a population of microbubbles. Slow-time spectrograms cal-
culated from the PCD measurements had an increase in signal energy at
the fundamental and sub-harmonic frequencies as the MI of the FUS beam
applied to microbubbles was increased (Fig. 3.5). Similarly, the plots of
cavitation dose indicated an increase in stable cavitation dose as the MI of
the FUS beam applied to microbubbles increased (Fig. 3.6). The cavita-
tion dose is dependent on the equipment and configuration used for PCD
measurements, so these results cannot be used for direct comparisons be-
tween other studies. However, comparisons of cavitation doses can be drawn
between the microbubble and control measurements collected in this study.
The increase in the stable cavitation dose observed in the microbubble mea-
surements, which was not present in the control measurements, suggests that
stable cavitation of the microbubbles was induced. There are many differ-
ent low intensity FUS treatments, and the physical mechanisms that induce
therapeutic effects are not well-characterized for many treatments. There-
fore, we cannot claim that an imaging array can be used as an FUS source
for all low intensity treatments. However, the PCD results suggest that an
imaging array would be suitable for low intensity treatments that rely on
stable cavitation such as opening of the blood-brain barrier, for which stable
cavitation is the main physical mechanism at low to moderate pressures [64].
Multiple pulse lengths were used in the PCD experiment to determine
which pulse length could deliver a higher cavitation dose. The 160-cycle
FUS beam delivered a higher stable cavitation dose than the 25-cycle beam
at larger MI values, which aligns with previous findings that higher pulse
lengths can achieve a higher cavitation dose for a given MI [65, 66]. The 25-
cycle FUS beam was used at higher pressure levels than the 160-cycle beam
because the lower pulse length results in a lower duty cycle and poses less
risk of damaging the transducer. The 160-cycle FUS beam caused a slight
increase in the inertial cavitation dose at the highest MI value, while the 25-
cycle delivered a large increase in the inertial cavitation dose. However, the
25-cycle FUS beam had a more wideband pulse because the excitation pulse
was shorter in duration. It is possible that the increased inertial cavitation
dose was not caused by increased broadband noise, but was instead due to
wideband signal from the fundamental and subharmonic frequencies. No
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transient, high amplitude emissions were observed in the time domain PCD
data for either pulse length, which further suggests that inertial cavitation





Figure 3.2: Overview of therapy planning procedure captured in
tissue-mimicking phantom. (a) B-mode image captured of the treatment
region to align the imaging array and for segmentation of the treatment
region. (b) B-mode image after manual segmentation of treatment region.
The treatment region is outlined with a white line and the focal point grid
is depicted with red points. (c) B-mode image with FUS beam visualization
overlay to allow for monitoring of the FUS beam as the beam traverses





Figure 3.3: Demonstration of therapy planning in a rat tumor in vivo. (a)
B-mode image of treatment region. (b) B-mode image after manual
segmentation of treatment region. The treatment region is outlined with a
white line and the focal point grid is depicted with red points. (c) B-mode





Figure 3.4: Slow-time spectrograms of control PCD measurements captured
while using a diagnostic imaging array to apply an FUS beam to degassed
water. A 160-cycle tone burst at 5 MHz was used for the FUS beam. (a)
FUS beam with MI = 0.15. (b) FUS beam with MI = 0.57. (c) FUS beam





Figure 3.5: Slow-time spectrograms of PCD measurements captured while
using a diagnostic imaging array to apply an FUS beam to a population of
microbubbles in water. A 160-cycle tone burst at 5 MHz was used for the
FUS beam. (a) FUS beam with MI = 0.15. (b) FUS beam with MI = 0.57.




Figure 3.6: Cavitation doses calculated for 25-cycle and 160-cycle FUS
beams with varying MI values. Control measurements were collected in a
tank of degassed water without microbubbles. Data were not collected for
the 160-cycle FUS beam at high MI values to avoid damaging the imaging




FUS is a rapidly advancing therapeutic modality with many promising ap-
plications. We have presented a novel beam monitoring technique and an
inexpensive low intensity FUS treatment system, both with the goal of fa-
cilitating safe, straightforward, and cost-effective FUS therapies. The beam
monitoring technique uses ultrasonic backscatter to visualize the in situ in-
tensity field of the FUS beam. It was demonstrated that robust beam re-
constructions can be captured in non-homogeneous media by normalizing
the reconstructions using the echogenicity of a co-aligned B-mode image.
Because therapeutic effects are induced when an FUS beam intersects with
tissue, real-time beam visualization using ultrasonic backscatter could be
used for monitoring FUS therapies. The main benefit of this technique com-
pared to existing methods such as MR thermometry is its simplicity and low
cost. Beam visualization using ultrasonic backscatter could be easily imple-
mented in most FUS therapy systems by using a secondary imaging array to
passively receive backscatter or by receiving backscatter with the FUS source
itself.
The low intensity FUS therapy system allows for combined therapy plan-
ning, real-time beam monitoring using ultrasonic backscatter, and FUS treat-
ment using a single diagnostic imaging array. The therapy planning and
beam monitoring capabilities of the system were tested in vivo and in a
tissue-mimicking phantom while a mock FUS therapy was carried out. PCD
measurements indicated that an imaging array can induce stable cavitation
in a population of microbubbles and could therefore be suitable for adminis-
tering some low intensity FUS treatments. Implementing all components of
a low intensity FUS therapy using a single ultrasound probe could simplify
and reduce the cost of treatments. Furthermore, diagnostic imaging arrays
are already commonplace in research and clinical settings.
While the proposed therapy planning and beam monitoring methods have
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been demonstrated in vivo, they have not been tested while administering an
actual FUS therapy in vivo. In future work, the real-time beam visualization
technique could be used by itself to monitor an in vivo FUS therapy or could
be implemented in addition to an existing monitoring technique such as PCI
or MR thermometry to provide additional redundancy. The low intensity
FUS therapy system could be fully tested by administering an in vivo low
intensity mechanical-based FUS therapy such as opening of the blood-brain
barrier or sensitization of tumors to radiotherapy. The therapy outcomes
using the diagnostic imaging array system could then be used to compare
against conventional FUS therapy systems.
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